CHICAGO — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed the progression of geographic atrophy was mostly unchanged in trial participants, according to a speaker here.
“Based on the current analysis, the progression of geographic atrophy was mostly unchanged over 24 months in most of our subjects and comparable between treat-and-extend and the monthly regimen,” Peter J. Kertes, MD, FRCS(C), said at the American Society of Retina Specialists annual meeting.
The open-label CANTREAT trial included
Uncategorized